The drugmaker also tested its antibody treatment against, B.1.1.7, the variant first identified in the U.K., finding it to be just as effective as it had been against earlier versions of the novel coronavirus.
The studies were not conducted using humans, but rather a manufactured pseudovirus containing mutations found in the two variants. The researchers found that the variant discovered in South Africa affected a wider range of antibodies.
More articles on pharmacy:
US drug prices 256% higher than other countries, study shows
Oklahoma trying to give back $2M hydroxychloroquine stockpile
Most pregnant women shouldn’t get COVID-19 vaccines, WHO says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
